Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

roy W Beck

Showing results (11-20 of 350) with videos related to

Pageof 35
Sort By:
Diabetes Technology & Therapeutics|June 4, 2013
Performance comparison of the medtronic sof-sensor and enlite glucose sensors in inpatient studies of individuals with type 1 diabetesPeter Calhoun, John Lum, Roy W Beck, et al.
Endocrine|August 29, 2012
Continuous glucose monitoring in type 1 diabetesNelly Mauras, Larry Fox, Kimberly Englert, et al.
Diabetes Technology & Therapeutics|January 22, 2026
A Real-World Data Assessment of Pulmonary Toxicity of Inhaled Insulin for DiabetesTodd L Burstain, Irl B Hirsch, Roy W Beck
Diabetes Technology & Therapeutics|December 23, 2021
Effectiveness of Continuous Glucose Monitoring in Older Adults with Type 2 Diabetes Treated with Basal InsulinShichun Bao, Ryan Bailey, Peter Calhoun, et al.
Diabetes Technology & Therapeutics|October 23, 2023
A Comparison of Continuous Glucose Monitoring-Measured Time-in-Range 70-180 mg/dL Versus Time-in-Tight-Range 70-140 mg/dLRoy W Beck, Dan Raghinaru, Peter Calhoun, et al.
Diabetes Technology & Therapeutics|August 3, 2022
The Optimal Duration of a Run-In Period to Initiate Continuous Glucose Monitoring for a Randomized TrialDan Raghinaru, Peter Calhoun, Richard M Bergenstal, et al.
Journal of Diabetes Science and Technology|May 21, 2008
Diabetes research in children network:availability of protocol data setsKatrina J Ruedy, Roy W Beck, Dongyuan Xing, et al.
Ophthalmology|March 24, 2020
The Course of Visual Recovery after Optic Neuritis: Experience of the Optic Neuritis Treatment TrialRoy W Beck, Patricia A Cleary, Jye-Yu C Backlund, et al.
Diabetes Technology & Therapeutics|December 28, 2022
The Relationship Between Percent Time <70 mg/dL and Percent Time <54 mg/dL Measured by Continuous Glucose MonitoringRoy W Beck, Dan Raghinaru, Peter Calhoun, et al.
Diabetes Technology & Therapeutics|April 13, 2023
Concordance of Central Laboratory Hemoglobin A1c Measurements from Capillary Kits Compared to Venous Draws in the Insulin-Only Bionic Pancreas Pivotal TrialZoey Li, Peter Calhoun, Katrina J Ruedy, et al.
Pageof 35

Showing results (11-20 of 350) with videos related to

Sort By:
Pageof 35
Diabetes Technology & Therapeutics|June 4, 2013
Performance comparison of the medtronic sof-sensor and enlite glucose sensors in inpatient studies of individuals with type 1 diabetesPeter Calhoun, John Lum, Roy W Beck, et al.
Endocrine|August 29, 2012
Continuous glucose monitoring in type 1 diabetesNelly Mauras, Larry Fox, Kimberly Englert, et al.
Diabetes Technology & Therapeutics|January 22, 2026
A Real-World Data Assessment of Pulmonary Toxicity of Inhaled Insulin for DiabetesTodd L Burstain, Irl B Hirsch, Roy W Beck
Diabetes Technology & Therapeutics|December 23, 2021
Effectiveness of Continuous Glucose Monitoring in Older Adults with Type 2 Diabetes Treated with Basal InsulinShichun Bao, Ryan Bailey, Peter Calhoun, et al.
Diabetes Technology & Therapeutics|October 23, 2023
A Comparison of Continuous Glucose Monitoring-Measured Time-in-Range 70-180 mg/dL Versus Time-in-Tight-Range 70-140 mg/dLRoy W Beck, Dan Raghinaru, Peter Calhoun, et al.
Diabetes Technology & Therapeutics|August 3, 2022
The Optimal Duration of a Run-In Period to Initiate Continuous Glucose Monitoring for a Randomized TrialDan Raghinaru, Peter Calhoun, Richard M Bergenstal, et al.
Journal of Diabetes Science and Technology|May 21, 2008
Diabetes research in children network:availability of protocol data setsKatrina J Ruedy, Roy W Beck, Dongyuan Xing, et al.
Ophthalmology|March 24, 2020
The Course of Visual Recovery after Optic Neuritis: Experience of the Optic Neuritis Treatment TrialRoy W Beck, Patricia A Cleary, Jye-Yu C Backlund, et al.
Diabetes Technology & Therapeutics|December 28, 2022
The Relationship Between Percent Time <70 mg/dL and Percent Time <54 mg/dL Measured by Continuous Glucose MonitoringRoy W Beck, Dan Raghinaru, Peter Calhoun, et al.
Diabetes Technology & Therapeutics|April 13, 2023
Concordance of Central Laboratory Hemoglobin A1c Measurements from Capillary Kits Compared to Venous Draws in the Insulin-Only Bionic Pancreas Pivotal TrialZoey Li, Peter Calhoun, Katrina J Ruedy, et al.
Pageof 35